Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


10. March 2021 | 09:27 CET

BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad

  • Biotechnology
Photo credits: pixabay.com

We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.

time to read: 3 minutes by Nico Popp
ISIN: US09075V1026 , NL0015436031 , CA14161Y2006


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


BioNTech: What's next for the vaccine hopeful?

The BioNTech share was an investor favorite for many months. Even today, the stock still has a lot to offer fundamentally. The Company is a leader in mRNA technology and was the first to develop a vaccine against Covid-19 successfully. Currently, it shows that it has paid off to break new ground in vaccine development. BioNTech's preparation is extremely effective and, almost more importantly, can interrupt chains of infection. One of the reasons why more and more experts are now advocating that younger people should also be vaccinated with BioNTech. If people with many contacts are vaccinated with it, it can have a significant epidemiological effect, they believe.

In the stock market, the stock has lost about 27% in the past three months. Given the increase in the preceding months, this is not a significant blow, but momentum seems to have left the share. It is currently rather unlikely that the share will rush from one high to the next as it did in the fall. Even if BioNTech is an excellent company, the share is currently lacking esprit.

CureVac: Share does not gain momentum

Similar to BioNTech, the Tübingen-based competitor CureVac is also suffering. The Company has also focused on mRNA technology and has developed an effective vaccine currently undergoing approval procedures within the EU. A partner for the production of the vaccine has also been found in Novartis. Together, the two companies plan to bring 50 million doses to market this year. In 2022, the aim is to produce a further 200 million vaccine doses. On a three-month view, however, CureVac's stock is underperforming BioNTech, losing about 37%. It seems that once the first vaccines are ready for the market, the fantasy around the share fades.

Cardiol Therapeutics: Story and valuation are right here

Nevertheless, Covid-19 and its mutations will be with us for many years to come. The vaccine manufacturers mentioned above will also adapt their preparations and bring new versions to market. It is similar to what is already happening with flu vaccines. In the future, one focus is also likely to be on mitigating severe courses or successfully treating patients with various pre-existing conditions. The biotech Company Cardiol Therapeutics is developing its active ingredient CardiolRx™ to treat inflammatory heart disease in this context. For the treatment of sequelae in the course of Covid-19 disease, the compound has already passed through clinical phase 1 and a Phase 2/3 trial is commencing imminently. Studies are also planned for other indications, such as acute myocarditis and diastolic heart failure. The biotech company relies on a highly concentrated dose of cannabidiol for its active ingredient, ensuring that it is highly effective despite being taken orally. Pre-clinical studies show significant effects on diseased heart tissue. Cardiovascular complications are frequent consequences of severe courses in connection with Covid-19 and lead to many deaths independently of the pandemic.

Cardiol Therapeutics has also developed a commercial CBD preparation in addition to CardiolRx™. It is distinguished by its remarkable purity and freedom from THC. These preparations are particularly popular with elderly patients. With this second pillar, the biotech company now wants to take off on the stock market. Only recently, Cardiol Therapeutics announced that it has submitted its application to be listed on the Nasdaq, subject to the approval of the Nasdaq and the satisfaction of all applicable listing criteria and requirements. At the same time, the Company succeeded in raising an additional USD 10 million in capital through subscription rights. Cardiol Therapeutics thus has financial leeway and is unlikely to raise additional capital in the near future. The listing on Nasdaq should also ensure that the company's relative undervaluation compared to other biotech companies becomes even more visible on the market. A few weeks ago, the biotech company GW Pharmaceuticals, which also uses active ingredients from the cannabis plant, was acquired in the USA for more than USD 7 billion. Cardiol Therapeutics' market capitalization is just over USD 100 million.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read